[The effect of angiotensin-II receptor antagonists on the vasoconstriction mechanisms in chronic heart failure].
Overall thirty-two patients with chronic heart failure (CHF) II-IV FC according to NYHA classification were studied for effects of irbesartan, an antagonist of receptors to angiotensine II on mechanisms of vasoconstriction. Noted as a result of the treatment conducted was a significant reduction in the content of vasoconstrictors of angiotensin II, vasopressin, and epinephrine as well as a tendency toward decrease in values for thromboxane A2 and adrenaline. Vasoconstrictor factors were found to have an important part in vascular control in realization of efficacy of irbesartan, an antagonist of receptors to angiotensin II, in CHF patients.
A N
AN
Korzh
L B
LB
Balkovaia
T I
TI
Bondarenko
D000328:Adult; D000368:Aged; D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D000077405:Irbesartan; D008297:Male; D008875:Middle Aged; D013777:Tetrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D014661:Vasoconstriction / Q000187:drug effects*
D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000804:Angiotensin II; D000077405:Irbesartan